Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

Imatinib

Gleevec

Stage Approved

Sponsor Novartis

Route oral tablet

Modality small molecule

Class KIT/PDGFRA TKI (type II)

Mechanism kinase inhibitor of KIT and PDGFRA

Target KIT (TEC-0117)

Target PDGFRA

Sources

fda, as of 2026-11-07

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b

Gleevec 400 mg N = 818 Gleevec 800 mg N = 822 Progression-free survival (months) Median 18.9 23.2 ... Overall survival (months) 49.0 48.7 ... The response rate was 68.5% for the 400 mg group and 67.6% for the 600 mg group. ... Thirty-six months of Gleevec treatment significantly prolonged RFS compared to 12 months of Gleevec treatment with a hazard ratio of 0.46 (95% CI: 0.32, 0.65)

Gleevec USPI section 14.9, Table 26 and adjuvant Study 1 and Study 2

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT00009906

Phase III Randomized, Intergroup Trial Assessing the Clinical Activity Of STI-571 at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the Kit Receptor Tyrosine Kinase (CD117)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT00041197

A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec™) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT00116935

Short (12 Months) Versus Long (36 Months) Duration of Adjuvant Treatment With the Tyrosine Kinase Inhibitor Imatinib Mesylate of Operable GIST With a High Risk of Recurrence

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

Imatinib Phase 3 dose trials (combined analysis on label)

Phase Phase 3

Status Completed

Enrollment 1640

Imatinib 400 mg daily

Dose 400 mg

Regimen once daily

Population unresectable or metastatic KIT (CD117) positive GIST

Estimand ITT

median progression-free survival: 18.9 months, median follow up 37.5 months

median overall survival: 49 months, median follow up 37.5 months

best overall response (complete 5.3% plus partial 46.1%): 51.4%, combined analysis, Sum of label complete response 43 (5.3%) and partial response 377 (46.1%)

Imatinib 800 mg daily

Dose 800 mg

Regimen 400 mg twice daily

Comparator imatinib 400 mg

Population unresectable or metastatic KIT (CD117) positive GIST

Estimand ITT

median progression-free survival: 23.2 months, median follow up 37.5 months

median overall survival: 48.7 months, median follow up 37.5 months

S0033 (one of the dose trials)

Registry NCT00009906

Phase Phase 3

Status Terminated

Enrollment 748

Start 2000-12

Primary completion 2007-05

Study completion 2014-11

Imatinib Phase 2 (400 vs 600 mg)

Phase Phase 2

Status Completed

Enrollment 147

Imatinib 400 mg

Dose 400 mg

Regimen once daily

Comparator imatinib 600 mg

Population KIT (CD117) positive unresectable or metastatic GIST

Estimand ITT

objective response rate (SWOG): 68.5%, up to 36 months

Imatinib 600 mg

Dose 600 mg

Regimen once daily

Comparator imatinib 400 mg

Population KIT (CD117) positive unresectable or metastatic GIST

Estimand ITT

objective response rate (SWOG): 67.6%, up to 36 months

Adjuvant Study 1 (ACOSOG Z9001)

Registry NCT00041197

Phase Phase 3

Status Completed

Enrollment 732

Start 2002-06

Primary completion 2007-04

Imatinib 400 mg for 12 months

Dose 400 mg

Regimen once daily for 12 months

Comparator placebo

Population resected primary GIST 3 cm or more

Estimand ITT

recurrence-free survival hazard ratio vs placebo (interim): 0.4 HR, median follow up 15 months

recurrence-free survival hazard ratio vs placebo (updated): 0.72 HR, median follow up 50 months

Adjuvant Study 2 (SSG XVIII)

Registry NCT00116935

Phase Phase 3

Status Completed

Enrollment 400

Start 2004-02

Primary completion 2010-12

Study completion 2010-12

Imatinib 400 mg for 36 months

Dose 400 mg

Regimen once daily for 36 months

Comparator imatinib for 12 months

Population resected high-risk KIT positive GIST

Estimand ITT

recurrence-free survival hazard ratio, 36 vs 12 months: 0.46 HR, median follow up 42 months

overall survival hazard ratio, 36 vs 12 months: 0.45 HR, median follow up 48 months